Array’s portfolio includes two drugs in more than 30 clinical trials for different kinds of cancer, particularly colorectal cancer. The companies said that is the third-most-common form of cancer:140,250 patients were diagnosed with cancer of the colon or rectum in the United States in 2018, and approximately 50,000 are estimated to die of their disease each year.
The proposed acquisition of Array “sets the stage to create a potentially industry-leading franchise for colorectal cancer alongside Pfizer’s existing expertise in breast and prostate cancers,” said Pfizer CEO Albert Bourla.
Array is essentially a start-up, with revenue of $174 million in its most recent fiscal year and a history of net losses. It is dwarfed in size by Pfizer which had revenue of $53.6 billion in 2018, making in the second-largest US pharmaceutical company behind only Johnson & Johnson (JNJ). Pfizer said it will use debt and cash reserves to make the purchase.
The purchase price of $48 a share represents a 62% premium over Array’s closing price on Friday. Shares of Array (ARRY) soared 60% in premarket trading on the purchase announcement, while shares of Pfizer (PFE) were little changed.
Pfizer is already in the midst of growing by combining its consumer healthcare business with that of GlaxoSmithKline (GLAXF), to create a joint venture with an estimated $12.7 billion in annual sales. That deal, expected to close in the second half of this year, will bring together Pfizer’s big over-the-counter products like Centrum and Caltrate with GSK’s top brands, including Excedrin and Nicorette.